Notícias e Atividades da Kiora Pharmaceuticals

Veja o organograma con seus 11 executivos principais

Biografias mais buscadas da Kiora Pharmaceuticals

• Brian Strem, Director, President and Chief Executive Officer
• Carmine Stengone, Director
• Praveen Tyle, Chairman of the Board

Recentes movimentos de executivos em Kiora Pharmaceuticals

• Eric Daniels, Chief Development Officer, deixará a Companhia em 17 de abr. de 2026  (Notícia publicada em 3 de abril de 2026).

Criar um alerta
para seguir os movimentos de executivos da Kiora Pharmaceuticals.

Kiora Pharmaceuticals possui 1.920 concorrentes concorrentes Sanofi (França), Moderna (Estados Unidos) e Eli Lilly (Estados Unidos).

Popular M&A news in Farmacêutica

• Eli Lilly has announced the acquisition of AtaiBeckley  (publicado em 17 de julho de 2026).
• Agenus acaba de anunciar uma arrecadação de fundos de 340 milhões de dólares. (publicado em 17 de julho de 2026).
• GSK adquiriu Nuvalent (publicado em 17 de julho de 2026).

Outros contatos sugeridos na indústria do Farmacêutica

• David Ricks - President, Chief Executive Officer and Chairman of the Board da Eli Lilly
• Richard Saynor - Chief Executive Officer da Sandoz
• Joaquin Duato - Chief Executive Officer and Chairman of the Board da Johnson & Johnson

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Kiora Pharmaceuticals

• Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium
• Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model
• Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
• Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway
• Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors
• Kiora Pharmaceuticals Announces Management Team Changes
• News Releases
• Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials
• Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference
• Retinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory Board
• View more press releases Close

Redes sociais sobre Kiora Pharmaceuticals

• Kiora Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
• Kiora Pharmaceuticals na LinkedIn, X (Twitter) e YouTube